Vivo Bio Tech credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025FY24Mar 2024
51.870.8
50.669.5
0.66×1.30×
0.65×1.28×
2.49×3.36×
2.43×3.30×
1.57×1.52×
39.8%56.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIVOBIOT₹13.98

Vivo Bio Tech Limited

· Pharma & Health
₹ CroreMcap ₹21.4 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Total Debt70.851.8
Net Debt69.550.6
Total Debt/Equity1.300.66
Net Debt/Equity1.280.65
Total Debt/EBITDA3.362.49
Net Debt/EBITDA3.302.43
Interest Coverage (EBIT/Interest)1.521.57
Total Debt/Total Capital %56.5639.85
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.